Roswitha Forstpointner

3.8k total citations
38 papers, 1.7k citations indexed

About

Roswitha Forstpointner is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Roswitha Forstpointner has authored 38 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pathology and Forensic Medicine, 21 papers in Genetics and 18 papers in Oncology. Recurrent topics in Roswitha Forstpointner's work include Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (11 papers). Roswitha Forstpointner is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (11 papers). Roswitha Forstpointner collaborates with scholars based in Germany, Netherlands and Australia. Roswitha Forstpointner's co-authors include Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling, Bernd Metzner, Hermann Einsele, John F. Seymour, Christiane Pott, Eva Hoster, H. Wandt and Roland Repp and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Roswitha Forstpointner

36 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roswitha Forstpointner Germany	15	1.5k	1.1k	732	235	188	38	1.7k
P. Solal-Céligny France	8	1.2k 0.8×	818 0.7×	539 0.7×	131 0.6×	389 2.1×	14	1.5k
Christopher Pocock United Kingdom	23	1.2k 0.8×	809 0.7×	1.1k 1.5×	125 0.5×	349 1.9×	64	2.1k
Dorothea Kofahl-Krause Germany	10	1.5k 1.0×	984 0.9×	921 1.3×	156 0.7×	256 1.4×	15	1.6k
J. Matthews United Kingdom	13	988 0.7×	664 0.6×	428 0.6×	126 0.5×	158 0.8×	20	1.1k
Ulrich von Grünhagen Germany	6	1.2k 0.8×	849 0.8×	789 1.1×	129 0.5×	197 1.0×	10	1.4k
David Belada Czechia	18	819 0.6×	604 0.5×	327 0.4×	124 0.5×	175 0.9×	167	1.1k
Elisabeth Wassner-Fritsch Switzerland	12	1.1k 0.8×	743 0.7×	768 1.0×	69 0.3×	124 0.7×	20	1.3k
Jamie Hirata United States	17	1.1k 0.7×	1.0k 0.9×	425 0.6×	64 0.3×	159 0.8×	64	1.4k
Jörg Kalla Germany	25	1.6k 1.1×	1.0k 0.9×	723 1.0×	271 1.2×	215 1.1×	40	2.0k
Xiaonan Hong China	20	930 0.6×	1.0k 0.9×	309 0.4×	416 1.8×	174 0.9×	71	1.7k

Countries citing papers authored by Roswitha Forstpointner

Since Specialization

Citations

This map shows the geographic impact of Roswitha Forstpointner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roswitha Forstpointner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roswitha Forstpointner more than expected).

Fields of papers citing papers by Roswitha Forstpointner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roswitha Forstpointner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roswitha Forstpointner. The network helps show where Roswitha Forstpointner may publish in the future.

Co-authorship network of co-authors of Roswitha Forstpointner

This figure shows the co-authorship network connecting the top 25 collaborators of Roswitha Forstpointner. A scholar is included among the top collaborators of Roswitha Forstpointner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roswitha Forstpointner. Roswitha Forstpointner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Christian, Vindi Jurinović, Martin Sökler, et al.. (2025). Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance. Haematologica. 110(12). 3022–3031.

Erickson, Nicole, Arndt Stahler, Maximilian Muenchhoff, et al.. (2022). Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV. Medical Oncology. 39(6). 104–104. 1 indexed citations

Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations

Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2017). Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen. Haematologica. 1 indexed citations

Hiddemann, Wolfgang, Martin Dreyling, Bernd Metzner, et al.. (2013). Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG). Blood. 122(21). 419–419. 3 indexed citations

Schulz, Christoph, Frank Kullmann, Volker Kunzmann, et al.. (2012). NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma.. Journal of Clinical Oncology. 30(15_suppl). 4072–4072. 1 indexed citations

Dreyling, Martin, Eva Hoster, Ursula Vehling‐Kaiser, et al.. (2011). Rituximab maintenance after combined immuno-chemotherapy significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. Data Archiving and Networked Services (DANS). 34. 200–201. 2 indexed citations

Forstpointner, Roswitha & Martin Dreyling. (2011). Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?. Current Hematologic Malignancy Reports. 6(4). 207–215. 2 indexed citations

Hoster, Eva, Bernd Metzner, Roswitha Forstpointner, et al.. (2009). Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.. Blood. 114(22). 880–880. 31 indexed citations

10.

Buske, Christian, Eva Hoster, Martin Dreyling, et al.. (2008). Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months. Blood. 112(11). 2599–2599. 14 indexed citations

11.

Christopeit, Maximilian, Georg Lenz, Roswitha Forstpointner, et al.. (2008). Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma. Chemotherapy. 54(4). 309–314. 10 indexed citations

12.

Forstpointner, Roswitha, Michael Unterhalt, Martin Dreyling, et al.. (2006). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 108(13). 4003–4008. 336 indexed citations

13.

Nickenig, Christina, Eva Hoster, Wolfgang Ludwig, et al.. (2006). Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Annals of Oncology. 18(1). 136–142. 13 indexed citations

14.

Hiddemann, Wolfgang, Roswitha Forstpointner, Martin Dreyling, et al.. (2005). Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood. 106(11). 920–920. 6 indexed citations

15.

Forstpointner, Roswitha, Roland Repp, Sandra Hermann, et al.. (2002). Rituximab zur Remissionsinduktion bei rezidivierten und refraktaeren indolenten Lymphomen und Mantelzell-Lymphomen: Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe fuer niedrig maligne Lymphome (GLSG). DMW - Deutsche Medizinische Wochenschrift. 127(43). 2253–2258. 1 indexed citations

16.

Forstpointner, Roswitha, Annette Hänel, Roland Repp, et al.. (2002). Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen. DMW - Deutsche Medizinische Wochenschrift. 127(43). 2253–2258. 6 indexed citations

17.

Forstpointner, Roswitha, F. Fiedler, Martin Gramatzki, et al.. (2001). The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG).. Data Archiving and Networked Services (DANS).

18.

Stemmler, Hans‐Joachim, Mahsa Malekmohammadi, Roswitha Forstpointner, et al.. (2001). Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Annals of Oncology. 12(10). 1393–1398. 51 indexed citations

19.

Perlet, C., H. Sittek, Roswitha Forstpointner, Marc L. Kessler, & Maximilian F. Reiser. (1999). Metastases to the breast from rhabdomyosarcoma: appearances on MRI. European Radiology. 9(6). 1113–1116. 28 indexed citations

20.

Gutensohn, Wolf, et al.. (1986). Production and Properties of Monoclonal Antibodies against Human Ecto-5′-Nucleotidase. Advances in experimental medicine and biology. 195 Pt B. 385–389. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact